恶性淋巴瘤的生物治疗策略  

Strategies of the Biological Therapy for Malignant Lymphoma

作　　者：刘彬[1] 张秀华[1] 平涛[1] 曹荣月[1] 

机构地区：[1]中国药科大学生物化学教研室,江苏南京210009

出　　处：《药学进展》2012年第5期207-215,共9页Progress in Pharmaceutical Sciences

基　　金：国家基础科学人才培养基金(No.J0630858);国家自然科学基金(No.30872393)

摘　　要：恶性淋巴瘤的发生率近年来呈逐年增长趋势,严重威胁着人类健康,传统手术和放化疗方法往往难以彻底治愈该病。随着生物技术的兴起和免疫学的快速发展,生物治疗策略已被越来越多地用于淋巴瘤的治疗。肿瘤疫苗、单克隆抗体和蛋白抑制剂的合理使用或与传统化疗药物联用可提高疗效,减少不良反应,提高淋巴瘤患者远期生存率。从免疫治疗和靶向治疗两方面介绍淋巴瘤生物治疗方法的研究近况。In recent years, an increasing incidence of malignant lymphoma has become a serious threat to the human health. The patients with malignant lymphoma cannot be completely cured by traditional surgery, radiation therapy and chemotherapy. With a rapid development of biotechnology and immunology, biological treatment has been widely used in lymphoma treatment. Suitable applications of cancer vaccine, monoclonal antibodies and protein inhibitors, or their combination with the traditional chemotherapy drugs could enhance the effect of treatment, reduce the adverse reactions and increase the rate of long-term survival. The recent studies of biological therapies were discussed within the context of lymphoma immune therapy and targeted therapy.

关 键 词：恶性淋巴瘤 生物治疗 免疫治疗 靶向治疗 肿瘤疫苗 单克隆抗体 

分 类 号：R733.1[医药卫生—肿瘤]